High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study-Reference-Cited by-同舟云学术

High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study

Published:2013-05-21 Issue:2 Volume:162 Page:240-249
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Gyan Emmanuel¹²³,Damotte Diane⁴,Courby Stéphane⁵,Sénécal Delphine¹,Quittet Philippe⁶,Schmidt-Tanguy Aline⁷,Banos Anne⁸,Le Gouill Steven⁹,Lamy Thierry¹⁰¹¹,Fontan Jean¹²,Maisonneuve Hervé¹³,Alexis Magda¹⁴,Dreyfus Francois¹⁵,Tournilhac Olivier¹⁶,Laribi Kamel¹⁷,Solal-Céligny Philippe¹⁸,Arakelyan Nina¹⁹,Cartron Guillaume⁶²⁰,Gressin Remy⁵²⁰,

Affiliation:

1. Department of Haematology and Cell Therapy; CHRU de Tours; Tours France

2. Team 2; CNRS UMR 7292; Faculty of Medicine; University François Rabelais; Tours France

3. Clinical Investigation Centre; INSERM U202; CHRU de Tours France

4. Department of Anatomy and Cytopathology; Hôpital Hôtel -Dieu; AP-HP, Paris France

5. Department of Haematology; CHU Michallon; Grenoble France

6. Department of Haematology; CHU; Montpellier France

7. Department of Haematology; CHU; Angers France

8. Department of Haematology; Centre Hospitalier de la Côte Basque; Bayonne France

9. Department of Clinical Haematology; CHU Hôtel Dieu; INSERM UMR892 équipe 10; Nantes France

10. Department of Haematology; CHU de Rennes; Rennes France

11. Université Rennes 1; Rennes France

12. Department of Haematology; CHU Minjoz; Besançon France

13. Department of Haematology; Centre Hospitalier Départemental de Vendée; La Roche-sur-Yon France

14. Department of Haematology; CHU la Source; Orléans France

15. Haematology Unit; Hôpital Hôtel-Dieu; AP-HP; Paris France

16. Department of Adult Haematology and Cell Therapy; CHU Hôtel-Dieu; Clermont-Ferrand France

17. Department of Haematology and Oncology; Centre Hospitalier; Le Mans France

18. Department of Haematology; Institut de Cancérologie; de l'Ouest, Nantes France

19. Department of Haematology; Centre Victor Dupouy; Argenteuil France

20. Team 7; INSERM U823; Institut Albert Bonniot; Université Joseph Fourier; Grenoble France

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12379/fullpdf

Reference23 articles.

1. Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma;Balzarotti;Annals of Oncology,1996

2. The International Prognostic Index Correlates to Survival in Patients With Aggressive Lymphoma in Relapse: analysis of the PARMA Trial;Blay;Blood,1998

3. Comparative activity of ifosfamide and cyclophosphamide;Brade;Cancer Chemotherapy and Pharmacology,1986

4. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group;Cheson;Journal of Clinical Oncology,1999

5. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma;Dunleavy;Blood,2009

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis;Cancer Research and Treatment;2023-07-15

2. Quantitative evaluation of therapy options for relapsed/refractory diffuse large B-cell lymphoma: A model-based meta-analysis;Pharmacological Research;2023-01

3. Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation;Leukemia & Lymphoma;2021-03-25

4. Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy;Supportive Care in Cancer;2021-02-24

5. Peripheral neuropathy in hematologic malignancies – Past, present and future;Blood Reviews;2020-09